This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This Advisory is based on TIP 37, Substance Abuse Treatment for Persons With HIV/AIDS. It highlights strategies and considerations for substance use disorder (SUD) treatment providers to effectively engage people with HIV in SUD treatment.

The report highlights the need for HIV treatment providers to address behavioral health concerns with HIV. The report urges providers to start with screening for mental health and substance use disorders, and offers strategies for providers to implement screening practices.